Surface Oncology to Present at the American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Surface Oncology SURF, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that data from the Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibody, will be presented at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, to be held virtually May 29-31.

A summary is provided below; the full poster will be placed on Surface Oncology's website following the presentation.

Presentation Type: e-poster (Abstract: 3064 / Poster: 128)

Title: Results of a first-in-human Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibody

Lead Author: Amita Patnaik

Session: Developmental Therapeutics - Immunotherapy

In 2018, Surface Oncology deprioritized the SRF231 clinical program and is concluding its Phase 1 study.

About Surface Oncology:

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (via targeting CD112R) or depleting regulatory T cells (via targeting CCR8). Surface's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contacts:

Investors

Matt Lane

matt@gilmartinir.com

617-901-7698

Media

Tom Donovan

tom@tenbridgecommunications.com

857-559-3397

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CarePress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!